Hypertrophe kardiomyopathie - Genetik und molekulargenetische diagnostik

Translated title of the contribution: Genetics and molecular genetic diagnostic of hypertrophic cardiomyopathy

A. Hafer, B. Mayer, H. Schunkert, Jeanette Erdmann*

*Corresponding author for this work


Hypertrophic cardiomyopathy (HCM) is the second most common cardiomyopathy after dilated cardiomyopathy (DCM), the prevalence of the disease is reported to be about 1/500 (1) to 1/2.500. Echocardiography has the most established diagnostic value for HCM. The clinical course is typically variable and the disease needs a differentiated therapy in any phase of disease. Only a minority of patients with HCM is at high risk for cardiac arrest, it is important to identify this subgroup. So far more than 300 mutations in 14 disease causing genes are identified but in only 50% of the patients with HCM the genetic defect is found. This is a challenge for the molecular genetic diagnostic. The current data are not sufficient to establish phenotype-genotype correlations with confidence. Systematic prospective clinical and molecular genetic studies will be required to elucidate the genetics of the disease. Now the 'Kompetenznetz Herzinsuffizienz' allows systematic molecular testing in a temporal and financially maintainable effort. The current development of chip-based DNA-sequencing may provide a rapid and sensitive technique to define the molecular cause of HCM in a single proband in the future.

Translated title of the contributionGenetics and molecular genetic diagnostic of hypertrophic cardiomyopathy
Original languageGerman
JournalMedizinische Welt
Issue number1-2
Pages (from-to)23-26
Number of pages4
Publication statusPublished - 01.2007


Dive into the research topics of 'Genetics and molecular genetic diagnostic of hypertrophic cardiomyopathy'. Together they form a unique fingerprint.

Cite this